- Home
- HYFM vs LPCN Comparison
HYFM vs LPCN Comparison
Compare HYFM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- LPCN
- Stock Information
- Founded
- HYFM 1977
- LPCN 1997
- Country
- HYFM United States
- LPCN United States
- Employees
- HYFM N/A
- LPCN N/A
- Industry
- HYFM Industrial Machinery/Components
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- LPCN Health Care
- Exchange
- HYFM Nasdaq
- LPCN Nasdaq
- Market Cap
- HYFM 17.3M
- LPCN 16.1M
- IPO Year
- HYFM 2020
- LPCN N/A
- Fundamental
- Price
- HYFM $3.97
- LPCN $3.27
- Analyst Decision
- HYFM Hold
- LPCN Strong Buy
- Analyst Count
- HYFM 2
- LPCN 2
- Target Price
- HYFM $7.00
- LPCN $9.00
- AVG Volume (30 Days)
- HYFM 6.9K
- LPCN 32.4K
- Earning Date
- HYFM 08-07-2025
- LPCN 08-07-2025
- Dividend Yield
- HYFM N/A
- LPCN N/A
- EPS Growth
- HYFM N/A
- LPCN N/A
- EPS
- HYFM N/A
- LPCN N/A
- Revenue
- HYFM $176,650,000.00
- LPCN $3,674,834.00
- Revenue This Year
- HYFM $5.45
- LPCN N/A
- Revenue Next Year
- HYFM $5.33
- LPCN N/A
- P/E Ratio
- HYFM N/A
- LPCN N/A
- Revenue Growth
- HYFM N/A
- LPCN N/A
- 52 Week Low
- HYFM $1.50
- LPCN $2.68
- 52 Week High
- HYFM $8.55
- LPCN $7.90
- Technical
- Relative Strength Index (RSI)
- HYFM 58.98
- LPCN 52.27
- Support Level
- HYFM $3.51
- LPCN $3.10
- Resistance Level
- HYFM $3.94
- LPCN $3.39
- Average True Range (ATR)
- HYFM 0.27
- LPCN 0.18
- MACD
- HYFM 0.01
- LPCN 0.02
- Stochastic Oscillator
- HYFM 94.24
- LPCN 39.77
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.